Busulfan sustained-release implantation agent for curing entity tumour

Busulfan one kind of sustained release implant treatment of solid tumors, wherein the sustained release implant comprising an anticancer effective amount of busulfan, sustained release excipients and an amount of release modulator. Release materials mainly glycolic acid and glycolic acid copolymers, polifeprosan, poly (L- lactide -co- propyl phosphate) or a combination thereof, which can be degraded and absorbed in the process of busulfan local slow release of the tumor, thus significantly reducing systemic toxicity while also maintaining local tumor effective drug concentration. The anti-tumor topical sustained release implant placed not only reduces systemic toxicity busulfan, while selectively increase local drug concentration in the tumor, enhance the therapeutic effect of chemotherapy drugs and radiation therapy of non-surgical therapy. Solid tumors, including pancreatic, lung cancer, liver cancer, breast cancer, brain tumor, ovarian cancer, prostate cancer, esophageal cancer, lymphoma, osteosarcoma, colorectal cancer and the like.